期刊
HAEMATOLOGICA
卷 102, 期 7, 页码 1273-1280出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2016.154062
关键词
-
类别
资金
- U.S. National Cancer Institute [CA190863, CA193362]
- MD Anderson Cancer Center SPORE in Multiple Myeloma Career Development Award [CDP-060315]
- Developmental Research Program [DRP-00013585]
- American Cancer Society [127337-RSG-15-069-01-TBG]
- Leukemia Research Foundation
- National Natural Science Foundation of China [81470356]
- MD Anderson Institutional Research Grant for Basic Research
Despite advances in therapy, multiple myeloma remains incurable, with a high frequency of relapse. This suggests the need to identify additional factors that contribute to drug resistance. Our previous studies revealed that bone marrow adipocytes promote resistance to chemotherapy in myeloma through adipocyte-secreted adipokines, but the mechanism underlying this effect and the specific adipokines involved are not well understood. We proposed to determine the role of resistin, an adipokine that is secreted by adipocytes, in chemotherapy resistance in myeloma. We found that resistin abrogated chemotherapy-induced apoptosis in established myeloma cell lines and primary myeloma samples. Resistin inhibited chemotherapy-induced caspase cleavage through the NF-kappa B and PI3K/Akt pathways. Resistin also increased the expression and drug efflux function of ATP-binding cassette (ABC) transporters in myeloma cells through decreasing the expression of both DNA methyltransferases DNMT1 and DNMT3a and the methylation levels of ABC gene promoters. In vivo studies further demonstrated the protective effect of resistin in chemotherapy-induced apoptosis. Our study thus reveals a new biological function of resistin in the pathogenesis of myeloma, with the implication that targeting resistin could be a potential strategy to prevent or overcome multidrug resistance in myeloma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据